Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

424
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
424
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The vagus nerve activated by inflammation co-transmits acute visceral pain via the NTS-PVN pathway.

Brain, behavior, and immunity·2026
Same author

A novel <i>CRB1</i> variant presenting as Leber congenital amaurosis-8 with angle-closure glaucoma in a Chinese family.

International journal of ophthalmology·2026
Same author

Fisetin targets multiple signaling pathways to suppress microglia-mediated neuroinflammation and cognitive decline in Alzheimer's disease.

Neuropharmacology·2026
Same author

Earlier onset of chemotherapy-induced neuropathic pain in females by ICAM-1-mediated accumulation of perivascular macrophages.

Science advances·2025
Same author

Gallic acid and loganic acid attenuate amyloid-β oligomer-induced microglia damage via NF-КB signaling pathway.

Neuropharmacology·2024
Same author

Endocytosis Is a Key Mode of Interaction between Extracellular β-Amyloid and the Cell Membrane.

Biophysical journal·2023
Same journal

Artificial intelligence for diagnosis of keratoconus using Scheimpflug based corneal tomography.

International journal of ophthalmology·2026
Same journal

Falling short of the target: effective cataract surgical coverage and the road to 2030.

International journal of ophthalmology·2026
Same journal

Multimodal imaging features of optic disc melanocytoma in a Chinese population.

International journal of ophthalmology·2026
Same journal

Comparison of posterior scleral reinforcement surgery and repeated low-level red-light therapy in controlling high and super high myopia in Chinese children.

International journal of ophthalmology·2026
Same journal

CORRIGENDUM.

International journal of ophthalmology·2026
Same journal

Curcumin protects the diabetic mouse retina by modulating the Hippo-YAP signaling pathway.

International journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

4.3K

New options for uveitis treatment.

Yu He1, Song-Bai Jia, Wei Zhang

  • 1Department of Ophthalmology, Fuling Center Hospital of Chongqing City, Chongqing 408000, China ; Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.

International Journal of Ophthalmology
|November 7, 2013
PubMed
Summary
This summary is machine-generated.

Uveitis, a leading cause of blindness, has complex causes. Current treatments like steroids have side effects, but new therapies including gene therapy offer hope.

Keywords:
RNA interferencebiologic agentsgene therapyintravitreal implantsuveitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.3K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.7K

Related Experiment Videos

Last Updated: May 6, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

4.3K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.3K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.7K

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Uveitis is a significant global cause of vision loss.
  • The underlying causes and mechanisms of uveitis remain incompletely understood.
  • Conventional treatments, primarily steroids and immunosuppressants, are limited by systemic side effects.

Purpose of the Study:

  • To review recent advancements in the treatment of uveitis.
  • To highlight emerging therapeutic strategies beyond conventional methods.

Main Methods:

  • Literature review of recent studies on uveitis treatment.
  • Analysis of novel therapeutic approaches and their potential.

Main Results:

  • Conventional treatments (steroids, immunosuppressants) have limitations.
  • Intravitreal implants and biologic agents represent newer treatment options.
  • Gene therapy and RNA interference are promising future therapeutic avenues.

Conclusions:

  • The treatment landscape for uveitis is evolving with innovative approaches.
  • Newer therapies aim to improve efficacy and reduce systemic side effects.
  • Further research into novel treatments like gene therapy is warranted for uveitis management.